Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders - PubMed (original) (raw)
Review
. 2014 Jun;55(6):791-802.
doi: 10.1111/epi.12631. Epub 2014 May 22.
Maria Roberta Cilio, Helen Cross, Javier Fernandez-Ruiz, Jacqueline French, Charlotte Hill, Russell Katz, Vincenzo Di Marzo, Didier Jutras-Aswad, William George Notcutt, Jose Martinez-Orgado, Philip J Robson, Brian G Rohrback, Elizabeth Thiele, Benjamin Whalley, Daniel Friedman
Affiliations
- PMID: 24854329
- PMCID: PMC4707667
- DOI: 10.1111/epi.12631
Review
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
Orrin Devinsky et al. Epilepsia. 2014 Jun.
Abstract
To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant aspects of the physiology, mechanisms of action, pharmacology, and data from studies with animal models and human subjects. Cannabis has been used to treat disease since ancient times. Δ(9) -Tetrahydrocannabinol (Δ(9) -THC) is the major psychoactive ingredient and CBD is the major nonpsychoactive ingredient in cannabis. Cannabis and Δ(9) -THC are anticonvulsant in most animal models but can be proconvulsant in some healthy animals. The psychotropic effects of Δ(9) -THC limit tolerability. CBD is anticonvulsant in many acute animal models, but there are limited data in chronic models. The antiepileptic mechanisms of CBD are not known, but may include effects on the equilibrative nucleoside transporter; the orphan G-protein-coupled receptor GPR55; the transient receptor potential of vanilloid type-1 channel; the 5-HT1a receptor; and the α3 and α1 glycine receptors. CBD has neuroprotective and antiinflammatory effects, and it appears to be well tolerated in humans, but small and methodologically limited studies of CBD in human epilepsy have been inconclusive. More recent anecdotal reports of high-ratio CBD:Δ(9) -THC medical marijuana have claimed efficacy, but studies were not controlled. CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic-ischemic encephalopathy. However, we lack data from well-powered double-blind randomized, controlled studies on the efficacy of pure CBD for any disorder. Initial dose-tolerability and double-blind randomized, controlled studies focusing on target intractable epilepsy populations such as patients with Dravet and Lennox-Gastaut syndromes are being planned. Trials in other treatment-resistant epilepsies may also be warranted. A PowerPoint slide summarizing this article is available for download in the Supporting Information section here.
Keywords: Cannabidiol; Cannabis; Dravet syndrome; GPR55; Medical marijuana; Tetrahydroacannabinol.
Wiley Periodicals, Inc. © 2014 International League Against Epilepsy.
Figures
Figure 1
Comment in
- Commentary: medical marijuana survey & epilepsy.
Devinsky O. Devinsky O. Epilepsia. 2015 Jan;56(1):7-8. doi: 10.1111/epi.12853. Epub 2014 Nov 20. Epilepsia. 2015. PMID: 25413243 No abstract available.
Similar articles
- Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE, Szaflarski JP. Gaston TE, et al. Curr Neurol Neurosci Rep. 2018 Sep 8;18(11):73. doi: 10.1007/s11910-018-0882-y. Curr Neurol Neurosci Rep. 2018. PMID: 30194563 Review. - Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R. Hussain SA, et al. Epilepsy Behav. 2015 Jun;47:138-41. doi: 10.1016/j.yebeh.2015.04.009. Epub 2015 Apr 29. Epilepsy Behav. 2015. PMID: 25935511 - Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies.
Reddy DS. Reddy DS. Exp Neurol. 2023 Jan;359:114237. doi: 10.1016/j.expneurol.2022.114237. Epub 2022 Oct 4. Exp Neurol. 2023. PMID: 36206806 Review. - Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S, Trinka E, Striano P, Rocchi C, Salvemini S, Silvestrini M, Brigo F. Lattanzi S, et al. CNS Drugs. 2021 Mar;35(3):265-281. doi: 10.1007/s40263-021-00807-y. Epub 2021 Mar 22. CNS Drugs. 2021. PMID: 33754312 Free PMC article. - Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio N, Pietrafusa N, Cross HJ. Specchio N, et al. Epileptic Disord. 2020 Jan 1;22(S1):1-9. doi: 10.1684/epd.2019.1121. Epileptic Disord. 2020. PMID: 31941643
Cited by
- LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder.
Bidwell LC, Martin-Willett R, Melendez SN, Rosa L, Giordano G, Hutchison KE, Bryan AD. Bidwell LC, et al. PLoS One. 2024 Sep 30;19(9):e0308262. doi: 10.1371/journal.pone.0308262. eCollection 2024. PLoS One. 2024. PMID: 39348366 Free PMC article. Clinical Trial. - FDA-approved cannabidiol [Epidiolex®] alleviates Gulf War Illness-linked cognitive and mood dysfunction, hyperalgesia, neuroinflammatory signaling, and declined neurogenesis.
Kodali M, Madhu LN, Kolla VSV, Attaluri S, Huard C, Somayaji Y, Shuai B, Jordan C, Rao X, Shetty S, Shetty AK. Kodali M, et al. Mil Med Res. 2024 Aug 22;11(1):61. doi: 10.1186/s40779-024-00563-2. Mil Med Res. 2024. PMID: 39169440 Free PMC article. - Exploring the efficacy and safety of cannabidiol in individuals with epilepsy: an umbrella review of meta-analyses and systematic reviews.
Abbasi H, Abbasi MM, Pasand M, Mohtadi M, Bakhshimoghaddam F, Eslamian G. Abbasi H, et al. Inflammopharmacology. 2024 Oct;32(5):2987-3005. doi: 10.1007/s10787-024-01523-x. Epub 2024 Aug 21. Inflammopharmacology. 2024. PMID: 39167312 Review. - Discovery and Profiling of New Multimodal Phenylglycinamide Derivatives as Potent Antiseizure and Antinociceptive Drug Candidates.
Jakubiec M, Abram M, Zagaja M, Socała K, Panic V, Latacz G, Mogilski S, Szafarz M, Szala-Rycaj J, Saunders J, West PJ, Nieoczym D, Przejczowska-Pomierny K, Szulczyk B, Krupa A, Wyska E, Wlaź P, Metcalf CS, Wilcox K, Andres-Mach M, Kamiński RM, Kamiński K. Jakubiec M, et al. ACS Chem Neurosci. 2024 Sep 4;15(17):3228-3256. doi: 10.1021/acschemneuro.4c00438. Epub 2024 Aug 21. ACS Chem Neurosci. 2024. PMID: 39166702 Free PMC article. - Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review.
Dyck GJB, Maayah ZH, Eurich DT, Dyck JRB. Dyck GJB, et al. Schizophr Bull Open. 2021 Nov 28;3(1):sgab053. doi: 10.1093/schizbullopen/sgab053. eCollection 2022 Jan. Schizophr Bull Open. 2021. PMID: 39144756 Free PMC article.
References
- Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009;66:95–105. - PubMed
- Joy JE, Watson SJ, Jr, Benson JA., Jr . Marijuana and medicine: assessing the science base. National Academies Press; 1999. - PubMed
- Abel EL. Marihuana, the first twelve thousand years. New York: Plenum Press; 1980.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical